Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
STAAR Surgical Co Market Cap
Based on ratings from 5 stock analysts, the STAAR Surgical Co stock price is expected to increase by 55.93% in 12 months. This is calculated by using the average 12-month stock price forecast for STAAR Surgical Co. The lowest target is $37 and the highest is $60. Please note analyst price targets are not guaranteed and could be missed completely.
STAAR Surgical Co has a total of 5 Wall St Analyst ratings. There are 3 buy ratings, 2 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that STAAR Surgical Co will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of STAA.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Thomas Stephan Stifel | Buy | $44 | Maintains | Aug 26, 2024 |
| David Saxon Needham | Hold | Reiterates | Aug 8, 2024 | |
| Jon Young Canaccord Genuity | Hold | $41 | Maintains | Aug 8, 2024 |
| Patrick Wood Morgan Stanley | Underweight | $37 | Downgrade | Jul 15, 2024 |
| Ryan Zimmerman BTIG | Buy | $53 | Maintains | Jul 15, 2024 |
| David Saxon Needham | Hold | Reiterates | Jul 15, 2024 | |
| Ryan Zimmerman BTIG | Buy | $46 | Upgrade | Jun 11, 2024 |
| Matt O'Brien Piper Sandler | Neutral | $40 | Maintains | May 8, 2024 |
| David Saxon Needham | Hold | Reiterates | May 8, 2024 | |
| Jon Young Canaccord Genuity | Hold | $43 | Maintains | May 8, 2024 |
| Anthony Petrone Mizuho | Buy | $55 | Maintains | May 8, 2024 |
| Anthony Petrone Mizuho | Buy | $53 | Maintains | Apr 11, 2024 |
| Jon Young Canaccord Genuity | Hold | $46 | Maintains | Apr 8, 2024 |
| David Saxon Needham | Hold | Reiterates | Apr 4, 2024 | |
| Thomas Stephan Stifel | Buy | $50 | Maintains | Apr 1, 2024 |
| Thomas Stephan Stifel | Buy | $50 | Upgrade | Mar 11, 2024 |
| Anthony Petrone Mizuho | Buy | $45 | Maintains | Feb 28, 2024 |
| Matt O'Brien Piper Sandler | Neutral | $33 | Maintains | Feb 27, 2024 |
| David Saxon Needham | Hold | Downgrade | Dec 5, 2023 | |
| Patrick Wood Morgan Stanley | Equal-Weight | $35 | Initiates | Dec 4, 2023 |
When did it IPO
N/A
Staff Count
1,056
Country
United States
Sector/Industry
Healthcare/Medical Instruments & Supplies
CEO
Mr. Thomas G. Frinzi
Market Cap
$1.59B
In 2023, STAA generated $322.4M in revenue, which was a increase of 13.37% from the previous year. This can be seen as a signal that STAA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 05 Sep 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - STAAR Surgical shares fell over 15% post-Q2 earnings, despite raised full-year revenue guidance. US sales rose 25% YoY, with the company on track for 2026 financial targets' low end.
Why It Matters - STAAR Surgical's share decline contrasts with strong sales growth and raised revenue guidance, indicating potential undervaluation and future upside as it approaches 2026 targets.
Mon, 12 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Staar Surgical (STAA) is heavily reliant on international revenue, which is crucial for assessing its financial stability, growth potential, and stock price performance.
Why It Matters - Staar Surgical's dependence on international revenue affects its financial stability and growth outlook, influencing investor confidence and stock price volatility.
Fri, 09 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - STAAR Surgical Company will host its Q2 2024 earnings conference call on August 7, 2024, at 4:15 PM ET. Key executives will participate in the call.
Why It Matters - The STAAR Surgical Q2 2024 earnings call provides insights into the company's financial performance and future outlook, crucial for assessing investment potential and market trends.
Wed, 07 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - STAAR Surgical reported Q2 2024 net sales of $99.0 million, up 7% year-over-year. ICL sales also increased by 7%, with a gross margin of 79.2%, up from 76.6%.
Why It Matters - STAAR Surgical's strong Q2 results, with rising sales and improved gross margins, indicate robust demand for their products, potentially boosting investor confidence and stock performance.
Wed, 07 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Staar Surgical (STAA) reported Q3 earnings of $0.33 per share, exceeding estimates of $0.25, but down from $0.40 per share year-over-year.
Why It Matters - Staar Surgical's earnings beat estimates, indicating strong performance. However, the decline from last year raises concerns about future growth potential, impacting investor sentiment.
Wed, 07 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Staar Surgical (STAA) reported its revenue and EPS for Q2 2024; investors should compare these figures against Wall Street estimates and year-over-year performance.
Why It Matters - Comparing Staar Surgical's revenue and EPS to Wall Street estimates and prior year results helps assess growth potential and market expectations, influencing investment decisions.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
